Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Haferkamp

Showing results (111-120 of 149) with videos related to

Pageof 15
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|January 30, 2026
Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysisGlenn Geidel, Sabrina Bänsch, Laura Adam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2025
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)Adi Diab, Paolo A Ascierto, Michele Maio, et al.
European Journal of Cancer (Oxford, England : 1990)|August 13, 2021
A benchmark for neural network robustness in skin cancer classificationRoman C Maron, Justin G Schlager, Sarah Haggenmüller, et al.
Cancers|April 12, 2022
Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in GermanyPeter Mohr, Emilie Scherrer, Chalid Assaf, et al.
Journal for Immunotherapy of Cancer|March 30, 2020
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patientsTeresa Amaral, Felix Kiecker, Sarah Schaefer, et al.
European Journal of Cancer (Oxford, England : 1990)|June 8, 2021
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastasesAnne Zaremba, Manuel Philip, Jessica C Hassel, et al.
Cancers|February 15, 2022
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or ToxicityElias A T Koch, Anne Petzold, Anja Wessely, et al.
Communications Medicine|September 10, 2024
Prospective multicenter study using artificial intelligence to improve dermoscopic melanoma diagnosis in patient careLukas Heinlein, Roman C Maron, Achim Hekler, et al.
Nature Cancer|May 16, 2025
MCSP<sup>+</sup> metastasis founder cells activate immunosuppression early in human melanoma metastatic colonizationSeverin Guetter, Courtney König, Huiqin Koerkel-Qu, et al.
European Journal of Cancer (Oxford, England : 1990)|December 25, 2025
Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment - Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADORegNoah Zimmermann, Julian Kött, Tim Zell, et al.
Pageof 15

Showing results (111-120 of 149) with videos related to

Sort By:
Pageof 15
Journal of the European Academy of Dermatology and Venereology : JEADV|January 30, 2026
Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysisGlenn Geidel, Sabrina Bänsch, Laura Adam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2025
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)Adi Diab, Paolo A Ascierto, Michele Maio, et al.
European Journal of Cancer (Oxford, England : 1990)|August 13, 2021
A benchmark for neural network robustness in skin cancer classificationRoman C Maron, Justin G Schlager, Sarah Haggenmüller, et al.
Cancers|April 12, 2022
Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in GermanyPeter Mohr, Emilie Scherrer, Chalid Assaf, et al.
Journal for Immunotherapy of Cancer|March 30, 2020
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patientsTeresa Amaral, Felix Kiecker, Sarah Schaefer, et al.
European Journal of Cancer (Oxford, England : 1990)|June 8, 2021
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastasesAnne Zaremba, Manuel Philip, Jessica C Hassel, et al.
Cancers|February 15, 2022
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or ToxicityElias A T Koch, Anne Petzold, Anja Wessely, et al.
Communications Medicine|September 10, 2024
Prospective multicenter study using artificial intelligence to improve dermoscopic melanoma diagnosis in patient careLukas Heinlein, Roman C Maron, Achim Hekler, et al.
Nature Cancer|May 16, 2025
MCSP<sup>+</sup> metastasis founder cells activate immunosuppression early in human melanoma metastatic colonizationSeverin Guetter, Courtney König, Huiqin Koerkel-Qu, et al.
European Journal of Cancer (Oxford, England : 1990)|December 25, 2025
Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment - Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADORegNoah Zimmermann, Julian Kött, Tim Zell, et al.
Pageof 15